Ravi K. Gupta, Hematology-Oncology Fellow at Larkin Health System, shared a post on LinkedIn:
“Thank you, Dr. Margaret Gatti-Mays, for your time, insights, and invaluable guidance during our conversation at the ASCO 2025 Annual Meeting. It was an honor to speak with a leader who is transforming the landscape of breast cancer care through innovation, research, and patient advocacy.
As Chief of Breast Medical Oncology at OSUCCC – James, Dr. Gatti-Mays is pioneering next-generation therapies—from developing the first-in-human NK cell–based immunotherapy for metastatic breast cancer to refining chemoimmunotherapy protocols in early-stage TNBC based on KEYNOTE-522 data.
Her dedication to advancing treatment for rare subtypes like small-cell breast cancer, managing immune-related adverse events, and shaping equitable immunotherapy guidelines through her leadership at SITC reflects a rare blend of scientific rigor and human-centered care.
“Yesterday’s clinical trials are tomorrow’s treatments.” That mindset drives real change—and it’s clear Dr. Gatti-Mays is leading the way. Grateful for the opportunity to learn from her and to share her vision with our audience.”
Read OncoDaily’s Special Articles about ASCO 2025: